![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
EY Krynetski, NF Krynetskaia, Y Yanishevski and WE Evans
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Thiopurine S-methyltransferase (TPMT), a cytosolic enzyme that exhibits genetic polymorphism, catalyzes S-methylation of mercaptopurine (MP) and thioguanine (TG), yielding S-methylated nucleobases that are inactive, whereas S-methylated nucleotides of these thiopurines are cytotoxic. A yeast-based heterologous expression system was therefore used to characterize human TPMT-catalyzed methylation of MP, TG, and their principal nucleotide metabolites [thioinosine monophosphate (TIMP) and thioguanosine monophosphate (TGMP), respectively]. MP, TG, TIMP, and TGMP were all substrates for human TPMT, exhibiting similar Michaelis-Menten kinetic parameters (Km, 10.6-27.1 microM; Vmax, 31-59 nmol/min/mg of TPMT). Consistent with these kinetic parameters, human leukemia cells (CEM) incubated for 24 hr with 10 microM MP or TG accumulated significantly higher (2.3-fold, p = 0.01) concentrations of methyl-TIMP after MP incubation than methyl-TGMP after TG incubation, due to the 2.7-fold higher concentration of TIMP after MP incubation, compared with TG nucleotides (TGN) after TG incubation. Moreover, intracellular accumulation of TGN was 2.5-fold greater after TG incubation than after MP incubation (p = 0.01). These data establish that MP, TG, and their principal nucleotide metabolites are comparable substrates for polymorphic TPMT, and they demonstrate significant differences in the accumulation of active TGN and methylated nucleotides when leukemia cells are treated with MP versus TG.
This article has been cited by other articles:
|
|
 |
|
  G. Zaza, M. Cheok, W. Yang, J. C. Panetta, C.-H. Pui, M. V. Relling, and W. E. Evans Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment Blood, September 1, 2005; 106(5): 1778 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gunnarsdottir and A. A. Elfarra DISTINCT TISSUE DISTRIBUTION OF METABOLITES OF THE NOVEL GLUTATHIONE-ACTIVATED THIOPURINE PRODRUGS CIS-6-(2-ACETYLVINYLTHIO)PURINE AND TRANS-6-(2-ACETYLVINYLTHIO)GUANINE AND 6-THIOGUANINE IN THE MOUSE Drug Metab. Dispos., June 1, 2003; 31(6): 718 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gunnarsdottir, M. Rucki, L. A. Phillips, K. M. Young, and A. A. Elfarra The Glutathione-activated Thiopurine Prodrugs trans-6-(2-Acetylvinylthio)guanine and cis-6-(2-Acetylvinylthio)purine Cause Less in Vivo Toxicity than 6-Thioguanine after Single- and Multiple-Dose Regimens Mol. Cancer Ther., November 1, 2002; 1(13): 1211 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Coulthard, L. A. Hogarth, M. Little, E. C. Matheson, C. P. F. Redfern, L. Minto, and A. G. Hall The Effect of Thiopurine Methyltransferase Expression on Sensitivity to Thiopurine Drugs Mol. Pharmacol., July 1, 2002; 62(1): 102 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dervieux, Y. Chu, Y. Su, C.-H. Pui, W. E. Evans, and M. V. Relling HPLC Determination of Thiopurine Nucleosides and Nucleotides in Vivo in Lymphoblasts following Mercaptopurine Therapy Clin. Chem., January 1, 2002; 48(1): 61 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dervieux, J. G. Blanco, E. Y. Krynetski, E. F. Vanin, M. F. Roussel, and M. V. Relling Differing Contribution of Thiopurine Methyltransferase to Mercaptopurine versus Thioguanine Effects in Human Leukemic Cells Cancer Res., August 1, 2001; 61(15): 5810 - 5816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Evans, Y. Y. Hon, L. Bomgaars, S. Coutre, M. Holdsworth, R. Janco, D. Kalwinsky, F. Keller, Z. Khatib, J. Margolin, et al. Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine J. Clin. Oncol., April 15, 2001; 19(8): 2293 - 2301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Relling, M. L. Hancock, G. K. Rivera, J. T. Sandlund, R. C. Ribeiro, E. Y. Krynetski, C.-H. Pui, and W. E. Evans Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus J Natl Cancer Inst, December 1, 1999; 91(23): 2001 - 2008. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
